Standard BioTools’ Q3 2025 earnings forecast: $4.2‑4.8 M revenue, 38‑42% gross margin, and $12.5 M cash—boosting its mass‑cytometry niche and recurring services outlook.

Standard BioTools Inc. is set to release its Q2 2025 earnings, with investors closely watching the company’s performance amidst broader market trends and financial updates from other key players.

Standard BioTools Inc. has partnered with Precision Health Research to launch a groundbreaking proteomics collaboration, leveraging the SomaScan 11K Assay to analyze 100,000 plasma samples and advance precision health and medicine.

Standard BioTools Inc. has announced the sale of its SomaLogic division to Illumina for up to $425 million, marking a significant transformation for the company and bolstering its capabilities in advancing health and disease research.